Loading insider details...
Beta
Latest Form 4 (Oct 3, 2026): Exercise/Conversion of 28,933 SYRE shares, $419.5K.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 3, 2026 | Spyre Therapeutics, Inc. (SYRE) | Exercise/Conversion | 28,933 | $419.5K |
| Sep 4, 2026 | Spyre Therapeutics, Inc. (SYRE) | Exercise/Conversion | 27,999 | $406.0K |
| Jan 14, 2026 | Spyre Therapeutics, Inc. (SYRE) | Grant/Award | 140,000 | n/a |
| Jan 17, 2025 | Spyre Therapeutics, Inc. (SYRE) | Grant/Award | 95,500 | n/a |
| Feb 3, 2024 | Spyre Therapeutics, Inc. (SYRE) | Grant/Award | 63,000 | n/a |
| Sep 5, 2023 | Aeglea BioTherapeutics, Inc. (AGLE) | Grant/Award | 13,495,255 | n/a |